Literature DB >> 10513656

Clinical disease associated with HIV-1 subtype B' and E infection among 2104 patients in Thailand.

P N Amornkul1, S Tansuphasawadikul, K Limpakarnjanarat, S Likanonsakul, N Young, B Eampokalap, J Kaewkungwal, T Naiwatanakul, J Von Bargen, D J Hu, T D Mastro.   

Abstract

BACKGROUND: Two HIV-1 envelope subtypes have accounted for virtually all infections in Thailand: subtype B' (Thai B), found mainly in injection drug users (IDU), and subtype E, found in over 90% of sexually infected persons and an increasing proportion of IDU in recent years. It remains unclear whether there are differences in pathogenesis associated with these HIV-1 subtypes.
METHODS: From November 1993 to June 1996, demographic, risk, clinical, and laboratory data were collected by enhanced surveillance from HIV-infected inpatients (> or =14 years) at an infectious disease hospital near Bangkok. HIV-1 subtype was determined by V3-loop peptide enzyme immunoassay (EIA). Because of confounding, multivariate analyses were stratified by risk category and controlled for sex and age.
RESULTS: The infecting HIV-1 subtype was determined for 2104 (94.9%) of 2217 HIV-infected patients with complete data: 284 (13.5%) were subtype B', 1820 (86.5%) were E. Specimens from 113 (5.1%) patients were non-reactive or dually reactive on peptide EIA and were excluded. Among IDU, 199 (67.2%) had subtype B', and 97 (32.7%) had E. IDU accounted for 70.1% (199/284) of patients with subtype B' and 5.3% (97/1820) of those with E. Patients infected with HIV-1 subtypes B' or E had similar spectrums of opportunistic infections (OI), levels of immunosuppression, and in-hospital mortality rates. Of patients who did not inject drugs, more patients infected with subtype E had extrapulmonary cryptococcosis than those with subtype B' (adjusted odds ratio, 2.6; 95% confidence interval, 1.28-5.37).
CONCLUSION: HIV-1 subtypes B' and E seem to be associated with similar degrees of immunosuppression and, with one exception, with similar OI patterns. These data do not suggest an association between HIV-1 subtype and differences in pathogenicity.

Entities:  

Mesh:

Year:  1999        PMID: 10513656     DOI: 10.1097/00002030-199910010-00020

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

2.  Segregation of human immunodeficiency virus type 1 subtypes by risk factor in Australia.

Authors:  Belinda L Herring; Ying C Ge; Bin Wang; Mala Ratnamohan; Frank Zheng; Anthony L Cunningham; Nitin K Saksena; Dominic E Dwyer
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

3.  Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.

Authors:  Pauli N Amornkul; Etienne Karita; Anatoli Kamali; Wasima N Rida; Eduard J Sanders; Shabir Lakhi; Matt A Price; William Kilembe; Emmanuel Cormier; Omu Anzala; Mary H Latka; Linda-Gail Bekker; Susan A Allen; Jill Gilmour; Patricia E Fast
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

4.  Association between HIV genotype, viral load and disease progression in a cohort of Thai men who have sex with men with estimated dates of HIV infection.

Authors:  Wanna Leelawiwat; Sarika Pattanasin; Anuwat Sriporn; Punneeporn Wasinrapee; Oranuch Kongpechsatit; Famui Mueanpai; Jaray Tongtoyai; Timothy H Holtz; Marcel E Curlin
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

5.  Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes.

Authors:  Sahra Abdulle; Lars Hagberg; Bo Svennerholm; Dietmar Fuchs; Magnus Gisslén
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

6.  Associating changes in the immune system with clinical diseases for interpretation in risk assessment.

Authors:  Michael I Luster; Dori R Germolec; Christine G Parks; Laura Blaciforti; Michael Kashon; Robert Luebke
Journal:  Curr Protoc Toxicol       Date:  2004

Review 7.  HIV-1 Latency and Latency Reversal: Does Subtype Matter?

Authors:  Indra Sarabia; Alberto Bosque
Journal:  Viruses       Date:  2019-11-28       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.